Baidu
map

Arch Gerontol Geriatr: 强壮上臂肌肉,远离骨质疏松症

2020-04-08 idiabetes idiabetes

新出现的证据显示上臂中部肌围的价值已经超出了其在营养不良领域的传统应用范围。按照年龄和BMI划分的组中上臂中部肌围的增加与骨质疏松症风险的降低之间有着密切的关联。

在临床实践中,上臂中部肌围(MAMC)可用来评价人体营养状况。其可反映肌肉质量、热量和蛋白质的充足性。既往研究数据显示,上臂中部肌围与老年男性死亡率之间存在显著的负相关。基于上臂中部肌围的易测量性,中国台湾学者基于第三次美国国家和营养检查调查(NHANES) III数据分析探讨了上臂中部肌围与骨质疏松的关系,结果显示较大的上臂中部肌围与男性患骨质疏松症的低风险相关。由此可见,MAMC可以作为评价男性骨质疏松症的简易指标之一。

研究概要

Wu及其同事评估了NHANES III中10090例40~90岁的成人(平均年龄47.8岁,女性52.3%,平均上臂中部肌围25.9 cm)的上臂中部肌围和股骨颈T值。研究人员依据上臂中部肌围将人群分为三组(T1、T2和T3)。上臂中部肌围计算公式为上臂中围(cm)-0.3142×三头肌皮褶(TS)厚度(mm)。应用Hologic QDR 1000骨密度计测量股骨颈骨密度值。采用多因素logistic回归模型评估上臂中部肌围和骨质疏松之间的相关性。使用–2.5或更低的T值来鉴定骨质疏松症。


主要结果

在充分校正的模型中,与上臂中部肌围13.8~23.1 cm的男性(T1)即上臂中部肌围最低组相比,上臂中部肌围26.9~44.1 cm(T3)(OR=0.34,95%CI:0.18~0.64)及23.2~26.8 cm(T2)(OR=0.47, 95%CI:0.3~0.75)的男性发生骨质疏松症的风险较小。研究人员指出,进行不同年龄和BMI范围的分析时,结果不会改变。此外,在充分校正的模型中,女性骨质疏松症发生风险不受上臂中部肌围差异的影响(表1)。

表1:基于logistic回归模型的男性和女性上臂中部肌围分类对骨质疏松风险的估计

注:
缩写:T(1,2,3),tertile(1,2,3)
调整协变量:
模型1=未调整。
模型2=模型1+年龄、性别、种族和BMI。
模型3=模型2+血清高密度脂蛋白、血清空腹血糖、血清总胆固醇、血清总胆红素、血清天冬氨酸转氨酶。
模型4=模型3+充血性心力衰竭、中风、恶性肿瘤和吸烟。


研究评

该研究的主要研究者吴立伟(Li-Wei Wu)教授评论道:“新出现的证据显示上臂中部肌围的价值已经超出了其在营养不良领域的传统应用范围。按照年龄和BMI划分的组中上臂中部肌围的增加与骨质疏松症风险的降低之间有着密切的关联。”

上臂中部肌围的增加可能是男性人群骨质疏松症的指标。将上臂中部肌围作为肌肉体积的替代物,对于检测老年男性的骨质疏松症既实用又方便。应考虑纳入上臂中部肌围评估骨质疏松症风险,将其作为定期体检时老年男性人群骨质疏松的筛查工具。

原始来源:
Chao YP, et al. Mid-arm muscle circumference as an indicator of osteoporosis in community-dwelling older men. Arch Gerontol Geriatr. 2019;doi:10.1016/j.archger.2019.103998.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2021683, encodeId=272620216830d, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri May 29 11:19:31 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592621, encodeId=dcc3159262181, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Fri Apr 10 13:19:31 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381489, encodeId=9dab381489d2, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51b45317427, createdName=张小护, createdTime=Wed Apr 08 23:24:33 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381487, encodeId=cf3b38148eb1, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Wed Apr 08 23:19:48 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2021683, encodeId=272620216830d, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri May 29 11:19:31 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592621, encodeId=dcc3159262181, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Fri Apr 10 13:19:31 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381489, encodeId=9dab381489d2, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51b45317427, createdName=张小护, createdTime=Wed Apr 08 23:24:33 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381487, encodeId=cf3b38148eb1, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Wed Apr 08 23:19:48 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
    2020-04-10 Eleven17
  3. [GetPortalCommentsPageByObjectIdResponse(id=2021683, encodeId=272620216830d, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri May 29 11:19:31 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592621, encodeId=dcc3159262181, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Fri Apr 10 13:19:31 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381489, encodeId=9dab381489d2, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51b45317427, createdName=张小护, createdTime=Wed Apr 08 23:24:33 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381487, encodeId=cf3b38148eb1, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Wed Apr 08 23:19:48 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
    2020-04-08 张小护

    不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2021683, encodeId=272620216830d, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Fri May 29 11:19:31 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592621, encodeId=dcc3159262181, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Fri Apr 10 13:19:31 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381489, encodeId=9dab381489d2, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=51b45317427, createdName=张小护, createdTime=Wed Apr 08 23:24:33 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381487, encodeId=cf3b38148eb1, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Wed Apr 08 23:19:48 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
    2020-04-08 qingfengqishi5

    学习了,学习了

    0

相关资讯

J Rheumatol:类风湿性关节炎患者骨质疏松症治疗指南的实施效果评估

RA患者对GIOP和PMOP预防不足。该人群骨质疏松症的治疗需要改善。

欧盟批准将Evenity(romosozumab)用于治疗绝经后妇女的骨质疏松症

欧盟委员会(EC)已授予Evenity(romosozumab)营销授权,用于治疗具有高风险骨折的绝经后妇女严重的骨质疏松症。

骨质疏松症中西医结合诊疗指南

据估计,到2050年我国常见OP性骨折(椎体、髋部和腕部)的医疗支出将达1 745亿元。中西医在OP的诊疗中各有优势,为明确中西医结合在OP诊疗中的作用,提高中西医结合诊疗水平,中国中西医结合学会骨伤科专业委员会组织专家,根据近年来OP最新诊疗进展,参考国内外指南和最新循证医学证据,结合临床经验,经过多次讨论制定本指南。本指南仅为学术性意见,实施时应结合患者和医疗具体情况。

骨质疏松症康复指南

骨质疏松症致残率较高、治疗周期较长、治疗费用高昂,给患者家庭和社会带来沉重的负担,所以,骨质疏松症的康复治疗就显得特别的重要。指南制订小组通过构建临床问题,系统查找、评价、综合证据,调查患者意愿,进行专家共识会,最终形成19条推荐意见。主要涉及骨质疏松症患者的康复评定、生活方式干预、物理治疗、作业治疗、康复工程、心理干预以及中医传统功法等方面的建议。

2019年ASBMR:abaloparatide治疗骨质疏松症的全新数据

Radius Health公司近日宣布,将在佛罗里达州奥兰多举行的2019年美国骨与矿物质研究学会(ASBMR)年会上发表五张海报,其中包括一项关于患者体验的真实世界研究结果。Radius Health的首席医疗官Charles Morris博士说:“特别令人兴奋的是,我们的第一张海报上有关于abaloparatide治疗骨质疏松症患者的真实世界数据。帮助更多患有绝经后骨质疏松症的女性是我们的最终

JCEM:地诺单抗治疗骨质疏松症期间感染风险

由此可见,在以骨质疏松症剂量的地诺单抗治疗期间,SAEI发生率更高。然而,任何感染或相关死亡的总体风险与对照组相似。这些发现需要在治疗开始之前充分考虑。

Baidu
map
Baidu
map
Baidu
map